Skip to content Skip to footer
Subscribe Now
NEWS

Vir Biotechnology Licenses Tobevibart & Elebsiran Combination to Norgine in EU, Australia and New Zealand

Shots: Vir Biotechnology has granted Norgine Pharma, an affiliate of Norgine exclusive commercial rights to the combination of tobevibart & elebsiran for the treatment of chronic hepatitis delta (CHD) in EU, Australia & New Zealand As per the deal, Vir will receive ~$64.5M (€ 55M) as initial reimbursement payment & ~ $581.3M (€ 495M) in…
December 17, 2025

Read more

NEWS

Vir Biotechnology Reports First Patient Enrolment in P-III (ECLIPSE 2) Trial of Tobevibart + Elebsiran for Chronic Hepatitis Delta (CHD)

Shots: Vir Biotechnology has enrolled the first pts in P-III (ECLIPSE 2) trial assessing tobevibart + elebsiran in CHD pts who have not achieved undetectable HDV RNA despite prior bulevirtide treatment Trial will assess CHD pts treated with bulevirtide for ≥24wks., randomized to either switch to tobevibart + elebsiran or continue bulevirtide, with the 1EP…
August 1, 2025

Read more